Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Total Liabilities
Based on the latest financial reports, Zhejiang Hisun Pharmaceutical Co Ltd (600267) has total liabilities worth CN¥4.62 Billion CNY (≈ $675.70 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Hisun Pharmaceutical Co Ltd - Total Liabilities Trend (1997–2025)
This chart illustrates how Zhejiang Hisun Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Zhejiang Hisun Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Zhejiang Hisun Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Hisun Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Federal Agricultural Mortgage Corporation
NYSE:AGM
|
USA | $35.01 Billion |
|
Wuxi Best Precision Machinery Co Ltd
SHE:300580
|
China | CN¥562.67 Million |
|
SALZGITTER UNSP.ADR 1/10
F:SZGA
|
Germany | €6.16 Billion |
|
TX Group AG
SW:TXGN
|
Switzerland | CHF797.00 Million |
|
Bestway Marine & Energy Technology Co Ltd
SHE:300008
|
China | CN¥3.30 Billion |
|
Formula Systems (1985) Ltd
F:FSY
|
Germany | €1.81 Billion |
|
Goldlok Toys Holdings Guangdong Co Ltd
SHE:002348
|
China | CN¥282.07 Million |
|
Companhia Siderurgica Nacional ADR
NYSE:SID
|
USA | $15.67 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Zhejiang Hisun Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Zhejiang Hisun Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Hisun Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Hisun Pharmaceutical Co Ltd (1997–2025)
The table below shows the annual total liabilities of Zhejiang Hisun Pharmaceutical Co Ltd from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥6.20 Billion ≈ $907.24 Million |
-16.14% |
| 2024-12-31 | CN¥7.39 Billion ≈ $1.08 Billion |
-20.19% |
| 2023-12-31 | CN¥9.26 Billion ≈ $1.36 Billion |
-11.33% |
| 2022-12-31 | CN¥10.45 Billion ≈ $1.53 Billion |
-13.14% |
| 2021-12-31 | CN¥12.03 Billion ≈ $1.76 Billion |
-4.56% |
| 2020-12-31 | CN¥12.60 Billion ≈ $1.84 Billion |
-8.56% |
| 2019-12-31 | CN¥13.78 Billion ≈ $2.02 Billion |
-4.78% |
| 2018-12-31 | CN¥14.48 Billion ≈ $2.12 Billion |
+5.19% |
| 2017-12-31 | CN¥13.76 Billion ≈ $2.01 Billion |
+8.19% |
| 2016-12-31 | CN¥12.72 Billion ≈ $1.86 Billion |
+15.53% |
| 2015-12-31 | CN¥11.01 Billion ≈ $1.61 Billion |
+21.87% |
| 2014-12-31 | CN¥9.03 Billion ≈ $1.32 Billion |
+12.72% |
| 2013-12-31 | CN¥8.01 Billion ≈ $1.17 Billion |
+49.20% |
| 2012-12-31 | CN¥5.37 Billion ≈ $786.00 Million |
+47.67% |
| 2011-12-31 | CN¥3.64 Billion ≈ $532.27 Million |
+14.48% |
| 2010-12-31 | CN¥3.18 Billion ≈ $464.96 Million |
+14.79% |
| 2009-12-31 | CN¥2.77 Billion ≈ $405.06 Million |
+7.62% |
| 2008-12-31 | CN¥2.57 Billion ≈ $376.38 Million |
+59.90% |
| 2007-12-31 | CN¥1.61 Billion ≈ $235.38 Million |
+4.30% |
| 2006-12-31 | CN¥1.54 Billion ≈ $225.67 Million |
+11.92% |
| 2005-12-31 | CN¥1.38 Billion ≈ $201.63 Million |
+40.92% |
| 2004-12-31 | CN¥977.76 Million ≈ $143.08 Million |
+12.13% |
| 2003-12-31 | CN¥871.96 Million ≈ $127.59 Million |
+16.15% |
| 2002-12-31 | CN¥750.69 Million ≈ $109.85 Million |
+45.84% |
| 2001-12-31 | CN¥514.75 Million ≈ $75.32 Million |
+14.64% |
| 2000-12-31 | CN¥449.01 Million ≈ $65.70 Million |
+6.34% |
| 1999-12-31 | CN¥422.24 Million ≈ $61.79 Million |
+47.02% |
| 1998-12-31 | CN¥287.20 Million ≈ $42.03 Million |
+70.26% |
| 1997-12-31 | CN¥168.68 Million ≈ $24.68 Million |
-- |
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small mol… Read more